ASX Share rice
Fri 14 May 2021 - 07:38:pm (Sydney)

NOX Share Price

NOXOPHARM LIMITEDNOXPharmaceuticals, Biotechnology & Life Sciences

NOX Company Information

Name:

Noxopharm Limited

Sector:

Healthcare

Industry:

Biotechnology

GIC Industry:

Biotechnology

GIC Sub Industry:

Biotechnology

Address:

828 Pacific Highway Gordon NSW Australia 2072

Phone:

61 2 9144 2223

Founder, CEO, MD & Director:

Dr. Graham Edmund Kelly

Company Sec.:

Mr. David James Franks B.Ec, BEc, CA, F Fin, JP.

Chief Financial Officer:

Mr. Shawn Van Boheemen

Chief Operating Officer:

Ms. Jeanette Bell

Chief Scientific Officer:

Dr. John Wilkinson

Chief Medical Officer:

Dr. Gisela Mautner

Company Overview:

Noxopharm Limited, a drug development company, focuses on the research and development of drugs to enhance radiotherapy in Australia and internationally. It primarily develops Veyonda, an adjuvant therapy in chemotherapy and radiotherapy for the treatment of late-stage cancers. The company also focuses on developing NYX-330, a PCSK9-inhibitor and LDL-cholesterol-lowering drug; NYX-104, a neuroprotectant that protects the brain from further damage after stroke and traumatic brain injury; and NYX-205, an anti-inflammatory drug for the treatment of nerve tissue inflammation. In addition, it develops anti-autoimmune drugs, such as IRAK4 and TPL2 inhibitors; and LuPIN for the combined therapy of Veyonda and 177Lu-PSMA-617. Noxopharm Limited has a partnership with Hudson Institute of Medical Research and a collaboration with The Australian National University to develop a better treatment for septic shock. The company was incorporated in 2015 and is based in Gordon, Australia.

NOX Share Price Information

Shares Issued:

278.88M

Market Capitalisation:

$139.44M

Revenue (TTM):

$5.93M

Revenue Per Share (TTM):

$0.03

Earnings per Share:

$-0.092

Profit Margin:

-0.0075

Operating Margin (TTM):

$-1.38

Return On Assets (TTM):

$-0.26

Return On Equity (TTM):

$-0

Quarterly Revenue Growth (YOY):

-0.64

Gross Profit(TTM):

$8.33M

NOX CashFlow Statement

CashFlow Date:

2020-06-30

Investments:

$337.82K

Change To Liabilities:

$767.48K

Total Cashflow From Investing Activities:

$337.82K

Net Borrowings:

$3.84M

Net Income:

$-272,093

Total Cash From Operating Activities:

$-11,137,958

Depreciation:

$241.45K

Other Cashflow From Investing Activities:

$340.82K

Change To Inventory:

$177.17K

Change To Account Receivables:

$-4,722,649

Sale Purchase Of Stock:

$11.01M

Capital Expenditures:

$3K

NOX Income Statement

Income Date:

2020-06-30

Income Before Tax:

$-999,570

Net Income:

$-272,090

Operating Income:

$-8,022,830

Interest Expense:

$3.47M

Total Revenue:

$8.34M

NOX Balance Sheet

Balance Sheet Date:

2020-06-30

Total Liabilities:

$7.19M

Total Stockholder Equity:

$12.87M

Total Assets:

$20.07M

Common Stock:

$41.63M

Other Current Assets:

$519.23K

Retained Earnings:

$-31,466,355

Other Liabilities:

$95.46K

Other Assets:

$348.07K

Cash:

$7.10M

Total Current Liabilities:

$6.69M

Short-Term Debt:

$4.34M

Property - Plant & Equipment:

$850.61K

Net Tangible Assets:

$12.87M

Long-Term Investments:

$6.54M

Total Current Assets:

$12.33M

Net Receivables:

$4.65M

Short-Term Investments:

$7.74M

Inventory:

$519.23K

Accounts Payable:

$1.79M

Non Currrent Assets (Other):

$122.84K

Short-Term Investments:

$7.74

Non Current Liabilities Total:

$508.75K

NOX Share Price History

NOX News

11 May, 2021
Noxopharm begins first-line sarcoma treatment testing for Veyonda.
27 Apr, 2021
Interim data in the NOXCOVID study suggests Veyonda provides protection against progression of the severe inflammation associated with COVID-19.
14 Apr, 2021
Noxopharm files septic shock treatment patent for Veyonda®
18 Mar, 2021
Noxopharm Limited announced Veyonda has been approved to move into the second and final stage of the NOXCOVID-1 clinical trial.
17 Feb, 2021
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
03 Dec, 2020
Noxopharm announces a discovery by Cornell Medical College published in Nature Immunology validating the novel DARRT anti-cancer treatment of Veyonda®
12 Nov, 2020
Noxopharm announces pilot study with Bristol Myers Squibb’s product
10 Sep, 2020
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
23 Jul, 2020
Noxopharm has claimed a breakthrough in the search for restoring immune function within "cold" microtumors, converting them to so-called "hot" tumors.